InvestorsHub Logo

H2R

Followers 42
Posts 2160
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: None

Thursday, 09/27/2018 4:11:49 PM

Thursday, September 27, 2018 4:11:49 PM

Post# of 4271
FDA Approval for Its Lower Dose Symjepi Product


Adamis Pharmaceuticals Corp. (NASDAQ:ADMP)
Intraday Stock Chart
Today : Thursday 27 September 2018

Click Here for more Adamis Pharmaceuticals Corp. Charts.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the emergency treatment of allergic reactions (Type I) including anaphylaxis.
Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “The approval of the lower dose form of Symjepi represents another milestone for the company. We are working closely with Sandoz to bring this product to market and hope that it, along with the higher (0.3mg) version, will be well received in the market.”



Just got it in my inbox!!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADMP News